These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 34854733)

  • 1. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
    Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
    J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
    Hutson TE; Liu FX; Dieyi C; Kim R; Krulewicz S; Kasturi V; Bhanegaonkar A
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1171-1181. PubMed ID: 34165322
    [No Abstract]   [Full Text] [Related]  

  • 3. Patterns of care and health care resource use among Medicaid-enrolled women with recurrent or metastatic cervical cancer.
    Leath CA; Nysenbaum J; Ting J; Zhang YJ; Fiori A; Pauly N
    J Manag Care Spec Pharm; 2023 May; 29(5):490-498. PubMed ID: 37121257
    [No Abstract]   [Full Text] [Related]  

  • 4. Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis.
    Vanderpoel J; Emond B; Ghelerter I; Milbers K; Lafeuille MH; Lefebvre P; Ellis LA
    Pharmacoecon Open; 2023 Jul; 7(4):617-626. PubMed ID: 37074589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States.
    Klink AJ; Chmielowski B; Feinberg B; Ahsan S; Nero D; Liu FX
    J Manag Care Spec Pharm; 2019 Aug; 25(8):869-877. PubMed ID: 30945965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.
    West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
    J Manag Care Spec Pharm; 2023 Jul; 29(7):749-757. PubMed ID: 37404067
    [No Abstract]   [Full Text] [Related]  

  • 9. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study.
    Lee DH; Isobe H; Wirtz H; Aleixo SB; Parente P; de Marinis F; Huang M; Arunachalam A; Kothari S; Cao X; Donnini N; Woodgate AM; de Castro J
    BMC Health Serv Res; 2018 Mar; 18(1):147. PubMed ID: 29490654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
    Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
    Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
    Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma.
    Tawbi H; Bartley K; Seetasith A; Kent M; Lee J; Burton E; Haydu L; McKenna E
    J Manag Care Spec Pharm; 2022 Mar; 28(3):342-353. PubMed ID: 35199578
    [No Abstract]   [Full Text] [Related]  

  • 13. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
    Margolis J; Barron JJ; Grochulski WD
    J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis.
    Yang J; Boytsov N; Carlson JJ; Barthold D
    J Manag Care Spec Pharm; 2023 Aug; 29(8):917-926. PubMed ID: 37523320
    [No Abstract]   [Full Text] [Related]  

  • 16. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
    To TM; Exuzides A; Abbass IM; Patel AM; Ta JT; Surinach A; Fuller RLM; Luo J
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1228-1239. PubMed ID: 36282937
    [No Abstract]   [Full Text] [Related]  

  • 17. Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis.
    Wallace A; Barron J; York W; Isenberg K; Franchino-Elder J; Sidovar M; Sand M
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1102-1110. PubMed ID: 31556820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
    Norden AD; Korytowsky B; You M; Kim Le T; Dastani H; Bobiak S; Singh P
    J Manag Care Spec Pharm; 2019 Apr; 25(4):428-436. PubMed ID: 30917077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data.
    Swami U; Aggarwal H; Zhou M; Jiang S; Kim J; Li W; Laliberté F; Emond B; Agarwal N
    Clin Genitourin Cancer; 2023 Oct; 21(5):517-529. PubMed ID: 37248148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
    Bilen MA; Robinson SB; Schroeder A; Peng J; Kim R; Liu FX; Bhanegaonkar A
    Oncologist; 2023 Sep; 28(9):790-798. PubMed ID: 37432283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.